Analyzing Scans

PRIME - Next generation EMRs for personalised medicine and clinical decision support

find out more


The primary aim

is to provide a personalized medicine approach for the management of Parkinson's disease that complements symptomatic treatment by adopting a holistic strategy which takes into account genes and their mutations, clinical subtypes, neuroimaging, personality and beliefs, lifestyle, biological aging and co-morbidities.

The secondary goal

is to use Internet of Things devices (smartphones, insoles, IMUs) to improve the knowledge about the individual course of the disease and the response to treatment so as to support individualized self-management approaches.

Capemed invests

in these two goals to upgrade its core product NetMed360 EMR (Electronic Medical Record) in order to be used for the needs of personalized medicine. The initial application and test case is Neurology and specifically Parkinson’s which calls for personalized approaches due to its complexity and diversity. Within the framework of PRIME, tools will be added to support Neurologists' decisions for the therapy as well as for self-management of patients.

The expected results include

  • Incorporating new knowledge and innovation into existing (NetMed360 EMR) and new products (SaaS Support for Medical Decisions). The health care value chain which includes new services and personalized treatment of Parkinson's will be evaluated. Particularly ontology-based knowledge, the symptoms’ assessment subsystem and pharmacogenetic information add value to the end result and significantly differentiate it from competition.

  • Disposal, firstly, in the Greek market and, then, in the Balkans of a state of the art, web based, electronic medical record with personalized medicine capabilities.

  • Better health care and more improved safety for patients. Appropriate antiparkinsonian treatment, resulting from PRIME, will provide to the Parkinsonians the ability to be independent in their daily activities, even during work, to ensure a good quality of life.

  • Reeduction of costs and social impact through better management of the disease, the financial consequences of which include both direct (costs of medicines and medical care) and indirect costs (early retirement or dismissal of the patient, reduced working hours for informal caregivers, the cost of extra-formal care at home).


PRIME is co‐financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE - INNOVATE (project code:T2EDK-05199)